Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1 CNS 1

Conditions

Pancreatic Neoplasms 1

Interventions

Fluorouracil 56 Specimen Handling 51 Oxaliplatin 49 Leucovorin 46 Magnetic Resonance Spectroscopy 45 Bevacizumab 43 Gemcitabine 39 Irinotecan 30 Cetuximab 27 Nivolumab 25 130-nm albumin-bound paclitaxel 25 Cisplatin 24 Biopsy 24 pembrolizumab 22 Paclitaxel 22 Capecitabine 19 atezolizumab 18 durvalumab 14 Taxes 14 Folfox protocol 14 Carboplatin 13 X-Rays 12 Radiotherapy 12 Cyclophosphamide 12 fludarabine 11 dehydroftorafur 10 Radiation 10 Albumin-Bound Paclitaxel 10 Surgical Procedures, Operative 9 Immunoglobulin G 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Exenatide × Gastrointestinal × 30 days × Clear all

NCT05663515 2026-06-02

EXCEED

AstraZeneca

24,000 enrolled

Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡